Literature DB >> 7919637

Physiological changes due to age. Implications for the prevention and treatment of thrombosis in older patients.

M T Nurmohamed1, H R Büller, J W ten Cate.   

Abstract

The risk of venous thromboembolism increases with age. This increasing risk is associated with a concurrent enhancement of coagulation activation and gradual development of a 'prethrombotic state'. This is reflected by increased levels of coagulation activation peptides in the elderly, as well as decreased activity of the fibrinolytic system. Moreover, with increasing age there is an increased incidence of comorbid conditions, which may, in themselves, be associated with an increased risk for the development of thrombosis. Accurate diagnostic techniques and strategies for treatment and prevention of deep vein thrombosis (DVT) are mandatory in order to prevent potentially fatal complications of DVT, such as pulmonary embolism. The feasibility of validated diagnostic techniques for detecting DVT, such as real-time B-mode ultrasonography, impedance plethysmography and contrast venography, is not significantly hampered in elderly patients. The same applies to strategies for prophylaxis and treatment of DVT, which are similar to those for younger patients, although formal studies in elderly patients with DVT are lacking.

Entities:  

Mesh:

Year:  1994        PMID: 7919637     DOI: 10.2165/00002512-199405010-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  93 in total

Review 1.  Overview of the management of thrombotic disorders.

Authors:  A S Gallus
Journal:  Semin Thromb Hemost       Date:  1989-04       Impact factor: 4.180

2.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

Review 3.  Heparin for prophylaxis of venous thromboembolism.

Authors:  E W Salzman
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

4.  Deep vein thrombosis of the leg. Is there a "high risk" group?

Authors:  V V Kakkar; C T Howe; A N Nicolaides; J T Renney; M B Clarke
Journal:  Am J Surg       Date:  1970-10       Impact factor: 2.565

5.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis.

Authors:  M T Nurmohamed; F R Rosendaal; H R Büller; E Dekker; D W Hommes; J P Vandenbroucke; E Briët
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

6.  The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study.

Authors:  R P Tracy; E G Bovill; L P Fried; G Heiss; M H Lee; J F Polak; B M Psaty; P J Savage
Journal:  Ann Epidemiol       Date:  1992-07       Impact factor: 3.797

7.  Low-dose heparin in proximal femoral fractures. Failure to prevent deep-vein thrombosis.

Authors:  H Svend-Hansen; V Bremerskov; J Gøtrik; P Ostri
Journal:  Acta Orthop Scand       Date:  1981-02

8.  Effect of low-dose heparin and dihydroergotamine on frequency of postoperative deep-vein thrombosis in patients undergoing post-traumatic hip surgery.

Authors:  G Lahnborg
Journal:  Acta Chir Scand       Date:  1980

9.  Detection of deep-vein thrombosis by real-time B-mode ultrasonography.

Authors:  A W Lensing; P Prandoni; D Brandjes; P M Huisman; M Vigo; G Tomasella; J Krekt; J Wouter Ten Cate; M V Huisman; H R Büller
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

View more
  12 in total

Review 1.  Preventing thromboembolic complications in older orthopaedic surgery patients: interventions and outcomes.

Authors:  J W Eikelboom; J S Ginsberg
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

Review 2.  A guide to venous thromboembolism risk factor assessment.

Authors:  G D Motykie; L P Zebala; J A Caprini; C E Lee; J I Arcelus; J J Reyna; E B Cohen
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

3.  Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.

Authors:  C J Dunn; K L Goa
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 4.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 5.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

6.  How to manage bleeding disorders in aging patients needing surgery.

Authors:  Mouhamed Yazan Abou-Ismail; Nathan T Connell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 7.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 8.  Aspirin for the prevention of cardiovascular events in the elderly.

Authors:  Isabelle Mahé; Alain Leizorovicz; Charles Caulin; Jean-François Bergmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Rational antithrombotic therapy and prophylaxis in elderly, immobile patients.

Authors:  E C van Gorp; D P Brandjes; J W ten Cate
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 4.271

10.  Predictors of venous thromboembolism in patients with COVID-19 in an underserved urban population: A single tertiary center experience.

Authors:  Drew H Barnes; Kevin Bryan Lo; Ruchika Bhargav; Fahad Gul; Robert DeJoy; Eric Peterson; Grace Salacup; Jerald Pelayo; Jeri Albano; Zurab Azmaiparashvili; Janani Rangaswami; Andres Mora Carpio; Gabriel Patarroyo-Aponte
Journal:  Clin Respir J       Date:  2021-04-28       Impact factor: 1.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.